A nanoparticle pan-Ebolavirus vaccine protected rodents against lethal Zaire and Sudan virus infections, according to a Nature Communications study. Weidle, Brunette, Wrenn, and colleagues report that the platform delivered cross-species protection against multiple filovirus species. The research addresses a persistent challenge in filovirus medicine: outbreaks can involve different Ebola virus species, each capable of causing severe disease. A pan-viral approach is designed to reduce the need for species-specific vaccine deployment. While rodent data is an early step, the results support continued evaluation of broadening strategies for epidemic preparedness in regions where multiple species may circulate.